en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
Interview and summary of 2021 in Biostock
January 20, 2022
Read the text in the link below.
Download attachment (pdf)
https://www.biostock.se/en/2022/01/elicera-well-positioned-to-thrive-in-2022/
< Back to press releases
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept